Sodium-glucose cotransporters that mediate active glucose absorption in the intestine (SGLT1) and glucose reabsorption in the kidney (SGLT2). SGLT1 in the gut brush border is insulin-independent and remains chronically open with frequent eating (>3 meals/day), preventing metabolic switching and contributing to insulin resistance.
SGLT1 is located on the apical membrane of intestinal enterocytes, using the sodium gradient (created by basolateral Na+-K+ ATPase) to drive glucose absorption against its concentration gradient. Each glucose molecule is transported with 2 sodium ions. Glucose then exits basolaterally via GLUT2. SGLT2 in the kidney proximal tubule reabsorbs ~90% of filtered glucose. The key metabolic issue: SGLT1 activity is NOT regulated by insulin—it remains open as long as glucose is present in the lumen. With meal frequency >21 times/week (>3 meals/day), the body never enters a fasted state, SGLT transporters stay chronically active, insulin signaling remains constant, and metabolic flexibility is lost. This prevents autophagy, ketogenesis, and fat oxidation.
Understanding SGLT physiology explains why meal frequency (not just composition) drives metabolic dysfunction. Constant SGLT1 activation with frequent eating maintains chronic hyperinsulinemia, prevents metabolic switching between glucose and fat oxidation, blocks autophagy, and drives insulin resistance. Therapeutic strategies include time-restricted eating (closing the feeding window), intermittent fasting, and (pharmaceutically) SGLT2 inhibitors for diabetes management. The cPNI principle: restore fasting periods to allow SGLT transporters to close and metabolic flexibility to return.
- SGLT1 in intestinal brush border is insulin-independent glucose transporter
- Uses sodium gradient to drive glucose absorption against concentration gradient
- Remains open chronically with >21 meals/week (>3 meals/day)
- SGLT2 in kidney reabsorbs 90% of filtered glucose
- Chronic activation prevents metabolic switching, autophagy, ketogenesis
- SGLT2 inhibitors (gliflozins) are diabetes therapeutics that promote glycosuria
- Time-restricted eating and intermittent fasting allow SGLT1 closure
- Critical target for restoring metabolic flexibility
- insulin — SGLT1 operates independently of insulin signaling
- enterocytes — express SGLT1 on apical brush border membrane
- brush border enzymes — work alongside SGLT1 in final digestion and absorption
- GLUT4 — insulin-dependent transporter that contrasts with insulin-independent SGLT1
- metabolic flexibility — lost when SGLT transporters remain chronically open
- autophagy — prevented by chronic SGLT1 activation and constant insulin signaling
- insulin resistance — develops from chronic SGLT1-mediated glucose influx
- time-restricted eating — intervention that allows SGLT1 closure and metabolic switching
- intermittent fasting — creates fasting periods where SGLT transporters close
- ketogenesis — blocked by chronic SGLT1 activity and glucose availability
- Type 2 Diabetes — treated with SGLT2 inhibitors that promote glucose excretion
- hyperinsulinaemia — maintained by chronic SGLT1-mediated glucose absorption
- meal frequency — >21 meals/week keeps SGLT1 chronically active
- glucose — actively transported by SGLT1 using sodium gradient
- sodium — cotransported with glucose via SGLT1 (2 Na+ per glucose)
- kidney — site of SGLT2 glucose reabsorption
- metabolic syndrome — driven by chronic SGLT activation and loss of fasting periods
- fat oxidation — prevented when SGLT-mediated glucose influx keeps insulin elevated
- circadian rhythm — disrupted by constant feeding and SGLT1 activation
- lipogenesis — driven by chronic insulin from constant SGLT1 glucose transport